Education
About Us
Working with TipRanks
Follow Us
Pharvaris N.V. (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
$26.42
-$0.46(-2.39%)
At close: 4:00 PM EST
$26.42
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$11.51 - $29.80
Previous CloseN/A
Volume14.65K
Average Volume (3M)179.55K
Market Cap
$1.61B
Enterprise Value$1.12B
Total Cash (Recent Filing)$329.29M
Total Debt (Recent Filing)$578.66K
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Apr 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding64,055,640
10 Day Avg. Volume147,645
30 Day Avg. Volume179,553
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)3.73
Price to Sales (P/S)0.00
P/FCF Ratio-8.29
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.58K
Enterprise Value/Ebitda-7.24
Forecast
1Y Price Target
$41.00Price Target Upside55.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyPhase 3 RAPIDe-3 topline results demonstrate a rapid, durable oral response with strong secondary endpoint performance and a clean safety profile, bolstering the drug's differentiation for on‑demand treatment.
Commercial And Pipeline PositioningAccelerating commercial preparations combined with sufficient cash to fund launch activities, plus confidence in a prophylactic program, position the company to compete with injectable therapies and expand market reach.
Regulatory Filing ReadinessManagement is compiling regulatory dossiers and views existing datasets as sufficient to support an NDA submission, which reduces regulatory uncertainty ahead of review.
Bears Say
Data ComparabilitySlight differences in retreatment protocols versus competitors make direct comparisons harder, creating uncertainty for payers and prescribers assessing relative benefit.
Physician Adoption RiskMarket uptake depends on becoming a preferred option among physicians, so prescribing habits and clinician preferences could constrain on‑demand revenue despite positive clinical data.
Research Conflicts Of InterestResearch providers' business relationships with covered companies may create perceived conflicts of interest that could undermine confidence in favorable reports.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $11.51 and its highest was $29.80 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $1.61B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Apr 14, 2026 which is in 66 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on Nov 12, 2025. The company reported -$0.709 earnings per share for the quarter, beating the consensus estimate of -$0.788 by $0.079.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 64,055,640 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of -$0.709 in its last earnings report, beating expectations of -$0.788. Following the earnings report the stock price went up 7.007%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (55.19% Upside)
$41.00 (55.19% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 900.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.68%
12-Months-Change
Fundamentals
Return on Equity
-51.81%
Trailing 12-Months
Asset Growth
13.93%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$41.00
▲(55.19% Upside)
Technical Analysis
Ownership Overview
―
Insiders
8.78% Mutual Funds
71.47% Other Institutional Investors
18.52% Public Companies and
Individual Investors